查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2014924

肝纖維化治療市場：按藥物類別、作用機制、給藥途徑和分銷管道分類的全球市場預測，2026-2032年

Liver Fibrosis Drugs Market by Drug Class, Mechanism Of Action, Route Of Administration, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肝纖維化治療市場價值將達到 171.2 億美元，到 2026 年將成長至 188.3 億美元，到 2032 年將達到 337 億美元，年複合成長率為 10.15%。

主要市場統計數據
基準年 2025 171.2億美元
預計年份：2026年 188.3億美元
預測年份 2032 337億美元
複合年成長率 (%) 10.15%

對影響肝纖維化治療發展和相關人員優先事項的不斷變化的治療、監管和商業性環境進行權威說明。

肝纖維化處於未滿足的醫療需求、科學創新和商業性機會三者交會的關鍵位置。過去十年，我們對創傷治療、細胞外基質重塑和免疫代謝的理解不斷深入，並將肝纖維化的進展從不可避免的臨床終點轉變為可治療的標靶。這種模式轉移正在加速開發更多樣化的治療方法，促進肝病學和免疫學專家之間的跨學科合作，並提升連接機制與臨床結果的轉化生物標記的重要性。

科學突破、治療方法擴展和創新試驗設計如何從根本上改變肝纖維化的治療策略和相關人員的行為。

肝纖維化領域正經歷一場變革，主要得益於科學突破、治療方法的多樣化以及臨床試驗框架的變革。對纖維化誘導訊號網路的分子層級解析使得標靶治療更加精準，而生物製藥、細胞和基因療法以及小分子化合物的設計進步則進一步拓展了治療手段。隨著治療方法的多樣化，研發人員越來越重視將作用機制與疾病表現型相匹配，優先研發能夠調節纖維化核心促進因素的藥物，而非僅僅抑制相關的發炎反應。

本研究評估了美國關稅政策的最新變化對肝纖維化治療藥物研發中的供應鏈韌性、籌資策略和商業規劃的影響。

美國近期關稅政策的變化為支撐藥品研發和商業化的全球供應鏈帶來了新的複雜性。關稅調整影響活性藥物成分的採購以及生物製藥生產所需特殊原料的採購。依賴跨境採購零件的製造商被迫重新評估其供應商合約、庫存策略和成本結構，以維持供應的連續性並保護利潤率。

將藥物類別、作用機制、給藥途徑和分銷管道聯繫起來的多方面細分洞察，有助於制定開發和商業化策略。

了解細分市場對於將研發和商業策略與治療機會相匹配至關重要。若依治療方法類別將治療方法分類，則可分為生物製藥、細胞療法、基因療法及小分子抑制劑。在生物製藥類別中，單株抗體和重組蛋白作為能夠實現標靶特異性和免疫反應調節的平台正日益受到關注。另一方面，小分子抑制劑既包括天然來源的骨架，也包括可口服給藥或作用於細胞內標靶的合成最佳化化合物。

影響多個全球醫療保健生態系統中監管參與、證據產生和商業性實施的區域發展和准入趨勢。

區域趨勢對研發重點、監理互動和商業性化途徑有顯著影響。在美洲，監管機構和保險支付方強調真實世界療效和基於價值的契約，這鼓勵申辦方制定能夠證明永續臨床療效和降低醫療成本的證據生成策略。該地區的臨床網路和學術機構也積極參與患者招募和生物標記檢驗活動，從而影響早期試驗設計和轉化研究合作。

在肝纖維化治療領域，企業策略、夥伴關係和平台能力如何融合，進而推動差異化的產品線和協作方式？

肝纖維化領域的企業策略以平台主導創新、標靶產品開發和策略合作的整合為特徵。生技公司正利用高度彈性的轉化研發管線和精準的病患辨識策略，推動差異化的作用機制和First-in-Class藥物的研發。大型製藥企業也日益尋求與創新者建立合作關係，以加速後期研發並拓展其治療產品組合，從而提供規模優勢、監管談判經驗和商業化基礎設施。

採取切實可行的策略性舉措，透過協調轉化生物標記、供應鏈韌性、與區域監管機構的合作以及夥伴關係模式，加速治療藥物的成功上市。

產業領導者應優先考慮一系列切實可行的舉措，使科學預期與實際商業性現實相契合。首先，他們應儘早整合轉化生物標記策略，以降低臨床計畫風險，並明確作用機制與臨床終點之間的關聯。這種契合將有助於與監管機構進行對話，並增強對支付方的價值提案。其次，他們應透過多元化關鍵原料供應商、評估區域生產方案以及製定緊急時應對計畫來增強價值鏈韌性，從而維持臨床和商業性的連續性。

採用嚴謹的混合方法研究途徑，結合專家訪談、系統性的二手文獻綜述和營運分析，以檢驗治療和商業性的發現。

本報告的研究融合了多種調查方法，以確保其觀點穩健可靠且基於實證。主要研究包括對肝病臨床專家、監管顧問、行業高管和供應鏈專家進行結構化訪談，以了解當前的臨床實踐模式、監管預期和營運限制。透過整合這些定性見解，我們對治療差異化進行了背景分析，並確定了影響研發和商業化策略的關鍵決策點。

一份權威的綜合分析報告，重點闡述了在科學、臨床開發、運營和商業性實施方面可採取的優先事項，以實現肝纖維化治療的持續療效。

總而言之，肝纖維化的治療格局正從概念設想轉向實際應用。生物目標知識和治療方法工程領域的科學進步正在拓寬可行的干涉措施範圍，而診斷和臨床試驗設計的創新則使得概念驗證（PoC）更有效率。同時，研發、生產和商業化團隊之間需要進行整合規劃，以應對從供應鏈變化到關稅相關採購考量等各種營運壓力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：肝纖維化治療市場：依藥物類別分類

  • 生物製藥
    • 單株抗體
    • 重組蛋白
  • 細胞療法
  • 基因治療
  • 小分子抑制劑
    • 天然產品
    • 合成化合物

第9章：肝纖維化治療藥物市場－依作用機轉分類

  • ASK1抑制劑
  • 半乳糖凝集素-3抑制劑
  • PPAR促效劑
    • PDOα
    • PPARδ
    • PPARγ
  • TGF-BETA抑制劑

第10章：肝纖維化治療市場：依給藥途徑分類

  • 注射藥物
    • 靜脈
    • 皮下
  • 口服

第11章：肝纖維化治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房

第12章：肝纖維化治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：肝纖維化治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：肝纖維化治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國肝纖維化治療藥物市場

第16章：中國肝纖維化治療藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Akero Therapeutics, Inc.
  • AstraZeneca plc
  • BioLineRx Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • FibroGen, Inc.
  • Galectin Therapeutics, Inc.
  • Galmed Pharmaceuticals Ltd.
  • Gilead Sciences, Inc.
  • Hepion Pharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Inventiva SA
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Madrigal Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Zydus Lifesciences Ltd.
Product Code: MRR-437A5D08AE2D

The Liver Fibrosis Drugs Market was valued at USD 17.12 billion in 2025 and is projected to grow to USD 18.83 billion in 2026, with a CAGR of 10.15%, reaching USD 33.70 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 17.12 billion
Estimated Year [2026] USD 18.83 billion
Forecast Year [2032] USD 33.70 billion
CAGR (%) 10.15%

An authoritative introduction to the evolving therapeutic, regulatory, and commercial context shaping liver fibrosis drug development and stakeholder priorities

Liver fibrosis occupies a pivotal intersection of unmet clinical need, scientific innovation, and commercial opportunity. Over the past decade, advances in understanding wound healing, extracellular matrix remodeling, and immunometabolism have reframed fibrotic progression as a tractable therapeutic target rather than an inexorable clinical endpoint. This paradigm shift has catalyzed more diverse therapeutic modalities, encourages cross-disciplinary collaboration between hepatology and immunology experts, and elevates the importance of translational biomarkers that link mechanism to clinical outcomes.

Clinicians, payers, and developers now converge on common priorities: improving diagnostic precision, intervening earlier in the disease course, and demonstrating durable reversal of fibrosis while ensuring safety for chronic administration. Concurrently, regulatory agencies are signaling a willingness to engage on novel endpoints and adaptive trial designs, contingent on rigorously validated surrogate measures. These dynamics create a complex environment where scientific promise must be balanced against operational realities such as supply chain resilience and reimbursement pathways.

Throughout this report, emphasis is placed on how emerging therapies, platform technologies, and stakeholder incentives interact to shape development strategies. The intent is to provide a clear, actionable synthesis that supports decision-makers who must navigate scientific complexity, regulatory nuance, and commercial imperatives simultaneously.

How scientific breakthroughs, modality expansion, and innovative trial designs are driving a fundamental transformation in liver fibrosis therapeutic strategies and stakeholder behavior

The liver fibrosis landscape is undergoing transformative shifts driven by scientific breakthroughs, modality diversification, and changes in clinical trial architecture. Molecular deconvolution of fibrogenic signaling networks has enabled more precise target identification, while advances in biologics, cell and gene therapies, and small molecule design have expanded the therapeutic toolkit. As modalities diversify, developers are increasingly matching mechanism to disease phenotype, prioritizing agents that modulate core drivers of fibrogenesis rather than broadly suppressing associated inflammation.

Clinical development is also being reshaped by innovations in trial design and patient identification. Noninvasive diagnostics and digital biomarkers are enabling earlier enrollment and more efficient assessment of biological effect. These tools facilitate shorter, more informative proof-of-concept studies that reduce risk and accelerate go/no-go decisions. At the same time, partnerships across industry, academia, and contract research organizations are growing in importance as teams combine complementary expertise and capabilities to address complex translational challenges.

Commercially, pricing and access strategies are evolving in tandem with therapeutic differentiation. Payers are focusing on value demonstration through real-world evidence and durable clinical benefit, which is prompting sponsors to incorporate health economics and outcomes research earlier in development. Taken together, these shifts indicate a maturing field where scientific innovation is increasingly paired with pragmatic, outcome-focused development pathways.

Assessing how recent United States tariff shifts have reshaped supply chain resilience, sourcing strategies, and commercial planning across liver fibrosis drug development

Recent tariff policy developments in the United States have introduced a layer of complexity to the global supply chains that underpin drug development and commercialization. Tariff adjustments affect both the procurement of active pharmaceutical ingredients and the sourcing of specialized biologics manufacturing inputs. Manufacturers that rely on cross-border component sourcing have needed to reassess supplier contracts, inventory strategies, and cost structures in order to preserve supply continuity and protect margins.

In response, many organizations have diversified their supplier base, reshored critical manufacturing steps, or expanded inventories of key raw materials to mitigate disruption. These operational shifts have also influenced outsourcing decisions and relationships with contract development and manufacturing organizations, prompting tighter collaboration and increased transparency around lead times and capacity constraints. Regulatory teams, in parallel, are managing the implications for product labeling, import documentation, and quality oversight when manufacturing footprints change.

Strategic pricing and reimbursement discussions have been affected as well, with commercial teams recalibrating launch strategies to account for potential increases in landed costs. Meanwhile, stakeholders across the value chain are placing higher priority on supply chain resilience, dual sourcing, and scenario planning. Collectively, these changes underscore the importance of integrating regulatory, operations, and commercial planning to maintain clinical momentum and ensure patient access amid evolving trade policies.

Multidimensional segmentation insights that connect drug class, mechanism of action, administration route, and distribution channels to inform development and commercialization strategy

Understanding segmentation is essential to aligning research and commercial strategies with therapeutic opportunity. When therapies are organized by drug class, the field spans biologic therapies, cell therapies, gene therapies, and small molecule inhibitors. Within the biologic category, attention centers on monoclonal antibodies and recombinant proteins as platforms that offer target specificity and modulated immune engagement, while small molecule inhibitors encompass both natural product-derived scaffolds and synthetically optimized compounds that enable oral dosing and intracellular target access.

Mechanism-based segmentation further refines prioritization by highlighting ASK1 inhibitors, galectin-3 inhibitors, PPAR agonists, and TGF beta blockers as distinct mechanistic approaches. The PPAR axis itself is subdivided into PPAR alpha, PPAR delta, and PPAR gamma, each presenting differentiated metabolic and fibrotic biology that can be matched to patient phenotypes and comorbidity profiles. Route of administration matters for adherence and chronic treatment planning; injectable therapies, administered either intravenously or subcutaneously, tend to support controlled pharmacokinetics and clinic-based dosing models, whereas oral formulations facilitate outpatient management and broader uptake.

Distribution channels influence commercial execution and patient access. Hospital pharmacies serve acute and inpatient settings where complex biologics and infusion therapies are delivered, online pharmacies enable convenience and continuity for stable chronic regimens, and retail pharmacies-comprising chain and independent outlets-drive outpatient dispensing and direct-to-patient accessibility. Together, these intersecting segmentation lenses offer a multidimensional framework to prioritize development, design clinical programs, and craft go-to-market strategies that reflect modality, mechanism, administration route, and distribution realities.

Regional development and access dynamics that shape regulatory engagement, evidence generation, and commercial execution across multiple global healthcare ecosystems

Regional dynamics exert a profound influence on development priorities, regulatory engagement, and commercial access pathways. In the Americas, regulatory agencies and payers emphasize real-world effectiveness and value-based contracting, which incentivizes sponsors to design evidence generation strategies that demonstrate durable clinical outcomes and cost-of-care impacts. Clinical networks and academic centers across the region also contribute to patient recruitment and biomarker validation efforts, shaping early-phase study design and translational research collaborations.

Across Europe, Middle East & Africa, regulatory harmonization efforts and varying healthcare delivery models require tailored approaches to clinical trial execution and market access planning. European regulatory pathways often prioritize comparability and demonstration of incremental benefit, while regional variations in health technology assessment processes mean that evidence packages must be calibrated to local payer expectations. In parts of the Middle East and Africa, constrained infrastructure and differing prevalence patterns influence the design of implementation studies and access programs.

The Asia-Pacific region presents diverse clinical and commercial environments, with strong capabilities in biologics manufacturing, growing clinical trial capacity, and rapid adoption of digital health tools. Country-specific regulations and reimbursement pathways necessitate early engagement with local stakeholders. Taken together, these regional contours underscore the need for adaptive regulatory strategies, culturally informed patient engagement, and evidence plans that align with payer and provider priorities across geographies.

How company strategies, partnerships, and platform capabilities are converging to drive differentiated pipelines and collaborative approaches in liver fibrosis therapeutics

Company strategies in liver fibrosis are characterized by a mix of platform-driven innovation, targeted product development, and strategic collaboration. Biotech firms are advancing differentiated mechanisms and first-in-class assets, leveraging nimble translational pipelines and focused patient-identification strategies. Larger pharmaceutical companies contribute scale, regulatory experience, and commercialization infrastructure, and increasingly seek partnerships with innovators to accelerate late-stage development and broaden therapeutic portfolios.

Contract research organizations and contract development and manufacturing organizations play a critical role in accelerating timelines and enabling flexible capacity for both biologics and small molecule programs. These partners support adaptive trial designs, complex supply chain coordination, and regulatory submissions across multiple jurisdictions. Strategic alliances, licensing agreements, and co-development deals are common as organizations combine strengths: scientific ingenuity from smaller developers paired with commercial and regulatory capabilities from established firms.

Across the competitive landscape, differentiation arises from clinical efficacy signals, safety profiles amenable to chronic administration, and the ability to demonstrate mechanistic engagement through validated biomarkers. Companies that integrate translational science, patient-centric trial designs, and robust commercial planning are positioned to navigate reimbursement complexities and stakeholder expectations more effectively. The emphasis on collaboration, rather than purely head-to-head competition, reflects the complexity of addressing fibrotic disease biology and the value of complementary capabilities.

Actionable strategic initiatives that align translational biomarkers, supply chain resilience, regional regulatory engagement, and partnership models to accelerate successful therapeutic launches

Industry leaders should prioritize a set of actionable initiatives that align scientific promise with operational and commercial realities. First, integrate translational biomarker strategies early to de-risk clinical programs and create clear links between mechanism of action and clinical endpoints. This alignment will facilitate regulatory dialogue and strengthen value propositions for payers. Second, invest in supply chain resilience by diversifying suppliers for critical inputs, evaluating regional manufacturing options, and establishing contingency plans that preserve clinical and commercial continuity.

Third, pursue strategic collaborations that combine complementary capabilities: emerging innovators should seek partners for late-stage development and commercialization, while established companies can accelerate innovation through targeted licensing and co-development agreements. Fourth, tailor regional strategies to local regulatory and payer landscapes, engaging health technology assessment bodies and regional clinical networks to ensure evidence packages meet local requirements. Finally, design commercial models that reflect route of administration and distribution dynamics: ensure appropriate clinic-based support for injectable therapies and frictionless retail and online fulfillment for oral regimens.

By executing these recommendations, organizations can translate scientific advances into durable clinical impact while managing operational complexity and aligning stakeholder incentives across development and commercialization pathways.

A rigorous mixed-methods research approach combining expert primary interviews, systematic secondary literature review, and operational analysis to validate therapeutic and commercial insights

The research behind this report combines multiple methodological approaches to ensure a robust and evidence-based perspective. Primary research included structured interviews with clinical experts in hepatology, regulatory advisors, industry executives, and supply chain specialists to capture current practice patterns, regulatory expectations, and operational constraints. These qualitative insights were synthesized to contextualize therapeutic differentiation and to illuminate decision points that influence development and commercialization strategies.

Secondary research encompassed a systematic review of peer-reviewed literature, clinical trial registries, and publicly available regulatory guidance to map mechanistic rationales, clinical endpoints, and translational biomarkers. Operational analysis leveraged industry reports on manufacturing capabilities, supply chain frameworks, and distribution models to assess practical implications for development and market entry. Throughout the process, triangulation of evidence was applied to validate conclusions and to ensure that interpretations reflected multiple perspectives.

Analytical rigor was maintained through iterative validation with subject matter experts and cross-functional reviewers. The methodology prioritized clarity and reproducibility, with an emphasis on linking mechanistic science to clinical trial design and commercial execution. This approach supports decision-makers seeking actionable intelligence grounded in both scientific evidence and operational feasibility.

A conclusive synthesis highlighting actionable priorities across science, clinical development, operations, and commercial execution to realize durable therapeutic impact in liver fibrosis

In summary, the liver fibrosis therapeutic landscape is transitioning from conceptual promise to pragmatic execution. Scientific advances in target biology and modality engineering have expanded the set of viable interventions, while innovations in diagnostics and trial design are enabling more efficient proof-of-concept work. At the same time, operational pressures-ranging from supply chain shifts to tariff-related sourcing considerations-require integrated planning across R&D, manufacturing, and commercial teams.

Success in this environment will hinge on the ability to align mechanistic clarity with translational biomarkers, to design patient-centric clinical programs that reflect route of administration and distribution realities, and to engage payers and regulators early with robust evidence strategies. Strategic collaborations and adaptive operational models will be key enablers, allowing organizations to combine scientific differentiation with scale and market access expertise.

The outcome-oriented approach advocated throughout this report emphasizes measurable clinical benefit, durable patient outcomes, and pragmatic pathways to access. Stakeholders that adopt data-driven development, prioritize supply chain resilience, and pursue partnerships that complement internal capabilities will be best positioned to convert scientific innovation into sustained clinical and commercial success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Liver Fibrosis Drugs Market, by Drug Class

  • 8.1. Biologic Therapies
    • 8.1.1. Monoclonal Antibodies
    • 8.1.2. Recombinant Proteins
  • 8.2. Cell Therapies
  • 8.3. Gene Therapies
  • 8.4. Small Molecule Inhibitors
    • 8.4.1. Natural Products
    • 8.4.2. Synthetic Compounds

9. Liver Fibrosis Drugs Market, by Mechanism Of Action

  • 9.1. ASK1 Inhibitors
  • 9.2. Galectin-3 Inhibitors
  • 9.3. PPAR Agonists
    • 9.3.1. PPAR Alpha
    • 9.3.2. PPAR Delta
    • 9.3.3. PPAR Gamma
  • 9.4. TGF Beta Blockers

10. Liver Fibrosis Drugs Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Intravenous
    • 10.1.2. Subcutaneous
  • 10.2. Oral

11. Liver Fibrosis Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy
    • 11.3.1. Chain Pharmacy
    • 11.3.2. Independent Pharmacy

12. Liver Fibrosis Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Liver Fibrosis Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Liver Fibrosis Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Liver Fibrosis Drugs Market

16. China Liver Fibrosis Drugs Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Akero Therapeutics, Inc.
  • 17.6. AstraZeneca plc
  • 17.7. BioLineRx Ltd.
  • 17.8. Boehringer Ingelheim International GmbH
  • 17.9. Bristol-Myers Squibb Company
  • 17.10. FibroGen, Inc.
  • 17.11. Galectin Therapeutics, Inc.
  • 17.12. Galmed Pharmaceuticals Ltd.
  • 17.13. Gilead Sciences, Inc.
  • 17.14. Hepion Pharmaceuticals, Inc.
  • 17.15. Intercept Pharmaceuticals, Inc.
  • 17.16. Inventiva S.A.
  • 17.17. Ionis Pharmaceuticals, Inc.
  • 17.18. Johnson & Johnson Services, Inc.
  • 17.19. Madrigal Pharmaceuticals, Inc.
  • 17.20. Merck & Co., Inc.
  • 17.21. Novartis AG
  • 17.22. Novo Nordisk A/S
  • 17.23. Pfizer Inc.
  • 17.24. Zydus Lifesciences Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVER FIBROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CELL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GENE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY NATURAL PRODUCTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SYNTHETIC COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ASK1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GALECTIN-3 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR ALPHA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR DELTA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR GAMMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY TGF BETA BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY CHAIN PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY INDEPENDENT PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 175. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 177. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 178. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 179. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 180. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 205. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 208. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 210. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 211. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 215. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 218. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 220. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 221. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL LIVER FIBROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY BIOLOGIC THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY PPAR AGONISTS, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA LIVER FIBROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, 2018-2032 (USD MILLION)